
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) – Stock analysts at HC Wainwright cut their FY2026 earnings estimates for shares of PMV Pharmaceuticals in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($1.35) for the year, down from their prior estimate of ($1.03). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.83) EPS.
PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.18).
Check Out Our Latest Analysis on PMV Pharmaceuticals
PMV Pharmaceuticals Stock Up 5.0%
Shares of PMVP stock opened at $1.27 on Friday. The firm has a market cap of $67.89 million, a price-to-earnings ratio of -0.82 and a beta of 1.52. The company’s 50 day moving average is $1.39 and its 200 day moving average is $1.31. PMV Pharmaceuticals has a 52-week low of $1.02 and a 52-week high of $1.91.
Institutional Trading of PMV Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. BML Capital Management LLC grew its position in shares of PMV Pharmaceuticals by 37.5% in the 3rd quarter. BML Capital Management LLC now owns 7,330,000 shares of the company’s stock worth $12,241,000 after buying an additional 2,000,000 shares during the last quarter. Eversept Partners LP purchased a new stake in PMV Pharmaceuticals during the first quarter valued at approximately $2,912,000. BlackRock Inc. purchased a new stake in PMV Pharmaceuticals during the second quarter valued at approximately $1,233,000. Stonepine Capital Management LLC acquired a new stake in PMV Pharmaceuticals in the second quarter valued at approximately $718,355. Finally, Walleye Capital LLC acquired a new stake in PMV Pharmaceuticals in the second quarter valued at approximately $450,000. 90.20% of the stock is currently owned by institutional investors.
PMV Pharmaceuticals Company Profile
PMV Pharmaceuticals is a biopharmaceutical company focused on developing precision cancer treatments. Its research centers on the tumor-suppressor protein p53, which is altered in many cancers, with the goal of restoring its function through targeted medicines. The company’s lead investigational drug, rezatapopt (also known as PC14586), is designed to reactivate a specific mutated form of p53 called Y220C. PMV has studied the drug in clinical trials for patients with advanced solid tumors carrying that mutation.
Read More
- Five stocks we like better than PMV Pharmaceuticals
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
